AMEX · AZTR
Healthcare · Biotechnology
$0.13
Up+$0.01 (+4.81%)
Updated Aug 22, 2026, 8:02 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AZTR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning AZTR.
AZTR research
Company profile and research snapshot.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2025 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 21, 2026
Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and
Benzinga · Aug 12, 2026
Anitra (AMEX:AZTR) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.12) by 54.55 percent. This is a 85.95 percent increase over losses of $(1.21) per share from the same
Benzinga · Jul 15, 2026
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value
Benzinga · Jul 15, 2026
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AZTR.
